CON
NEUTRAL
$22.82
Live
Concentra Group Holdings Parent, Inc. · NYSE
Target $29.0
(+27.1%)
$18.55
52W Range
$24.68
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 25, 2026
Market cap
$2.93B
P/E
17.55
ROE
48.1%
Profit margin
7.7%
Debt/Equity
5.01
Dividend yield
1.1%
AI Analysis
AI-powered fundamental assessment
Confidence
80%
Concentra Group Holdings presents a dichotomy between strong growth and precarious leverage. While the Piotroski F-Score of 4/9 indicates stable financial health, the extreme Debt/Equity ratio of 5.01 is a significant risk factor that likely inflates the impressive 48.07% ROE. The stock trades at a significant premium to its Graham Number ($9.46) but remains well below its growth-based intrinsic value ($38.35), suggesting a valuation gap that analysts believe will close, despite a currently bearish technical trend.
Key Strengths
Strong YoY earnings growth of 60.10%
Robust Return on Equity (ROE) of 48.07%
Reasonable Forward P/E of 13.73 compared to growth rates
Strong analyst consensus with a 'strong_buy' recommendation
Consistent double-digit revenue growth (15.90% YoY)
Key Risks
Excessive leverage with a Debt/Equity ratio of 5.01
Bearish technical trend (0/100 score)
Significant gap between current price and defensive Graham Number ($9.46)
Recent Q/Q EPS growth decline of -26.3%
Low insider buying activity
AI Fair Value Estimate
Based on comprehensive analysis
$26.5
+16.1% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
58
Moderate
55
82
70
35
50
AI Verdict
Speculative Growth
Key drivers: High leverage, Strong earnings growth, Valuation gap between Graham and Intrinsic values
Confidence
85%
Value
55/100
Ref P/E, PEG, Graham Number
Positives
- P/E is moderate at 17.55
- Trades below intrinsic value of $38.35
Watchpoints
- Price/Book is high at 7.46
- Current price is 141% above Graham Number
Future
82/100
Ref Growth rates
Positives
- 60.10% YoY Earnings Growth
- 15.90% Revenue Growth
Watchpoints
- Recent Q/Q EPS contraction
Past
70/100
Ref Historical trends
Positives
- Consistent revenue expansion
- Positive 1Y and 6M price performance
Watchpoints
- Low 5Y change (+3.3%) suggests long-term stagnation
Health
35/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 4/9 is stable
Watchpoints
- Debt/Equity of 5.01 is critically high
- Current ratio of 1.14 provides a thin liquidity cushion
Dividend
50/100
Ref Yield, Payout
Positives
- Low payout ratio (19.23%) ensures sustainability
Watchpoints
- Low dividend yield of 1.10%
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$22.82
Analyst Target
$29.0
Upside/Downside
+27.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for CON and closest competitors.
Updated 2026-04-24
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
CON
Concentra Group Holdings Parent, Inc.
Primary
|
+3.3% | +3.3% | +8.6% | +9.8% | +3.7% | -0.2% |
|
TXG
10x Genomics, Inc.
Peer
|
-88.0% | -57.2% | +199.1% | +76.3% | +20.0% | -7.4% |
|
SUPN
Supernus Pharmaceuticals, Inc.
Peer
|
+66.0% | +41.6% | +67.1% | +2.4% | +4.3% | +1.4% |
|
PRVA
Privia Health Group, Inc.
Peer
|
+4.4% | -7.2% | +1.4% | -5.9% | +11.3% | +7.4% |
|
ARQT
Arcutis Biotherapeutics, Inc.
Peer
|
-30.1% | +98.3% | +53.6% | +31.6% | -14.4% | -5.2% |
CON
Concentra Group Holdings Parent, Inc.
Primary
5Y
+3.3%
3Y
+3.3%
1Y
+8.6%
6M
+9.8%
1M
+3.7%
1W
-0.2%
TXG
10x Genomics, Inc.
Peer
5Y
-88.0%
3Y
-57.2%
1Y
+199.1%
6M
+76.3%
1M
+20.0%
1W
-7.4%
SUP
Supernus Pharmaceuticals, Inc.
Peer
5Y
+66.0%
3Y
+41.6%
1Y
+67.1%
6M
+2.4%
1M
+4.3%
1W
+1.4%
PRV
Privia Health Group, Inc.
Peer
5Y
+4.4%
3Y
-7.2%
1Y
+1.4%
6M
-5.9%
1M
+11.3%
1W
+7.4%
ARQ
Arcutis Biotherapeutics, Inc.
Peer
5Y
-30.1%
3Y
+98.3%
1Y
+53.6%
6M
+31.6%
1M
-14.4%
1W
-5.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
17.55
Forward P/E
13.73
PEG Ratio
N/A
P/B Ratio
7.46
P/S Ratio
1.36
EV/Revenue
2.31
EV/EBITDA
11.84
Market Cap
$2.93B
Profitability
Profit margins and return metrics
Profit Margin
7.69%
Operating Margin
13.24%
Gross Margin
28.34%
ROE
48.07%
ROA
8.03%
Growth
Revenue and earnings growth rates
Revenue Growth
+15.9%
Earnings Growth
+60.1%
Q/Q Revenue Growth
+15.92%
Q/Q Earnings Growth
+61.2%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
5.01
High debt
Current Ratio
1.14
Good
Quick Ratio
1.0
Good
Cash/Share
$0.62
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.5B
Gross Margin
26.1%
Op. Margin
12.9%
Net Margin
6.4%
Total Assets
$2.9B
Liabilities
$2.4B
Equity
$0.4B
Debt/Equity
6.20x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
83%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-26
$0.28
2025-11-06
$0.38
+0.6% surprise
2025-08-07
$0.35
-5.1% surprise
Healthcare Sector Comparison
Comparing CON against 537 companies in the Healthcare sector
(28 bullish, 159 neutral, 350 bearish)
P/E Ratio
17.55
This Stock
vs
80.17
Sector Avg
-78.1%
(Discount)
Return on Equity (ROE)
48.07%
This Stock
vs
-91.87%
Sector Avg
-152.3%
(Below Avg)
Profit Margin
7.69%
This Stock
vs
-16.49%
Sector Avg
-146.7%
(Weaker)
Debt to Equity
5.01
This Stock
vs
2.73
Sector Avg
+83.5%
(Higher)
Revenue Growth
15.9%
This Stock
vs
129.42%
Sector Avg
-87.7%
(Slower)
Current Ratio
1.14
This Stock
vs
4.57
Sector Avg
-75.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
CON
Concentra Group Holdings...
|
NEUTRAL | $2.93B | 17.55 | 48.1% | 7.7% | $22.82 | |
|
TXG
10x Genomics, Inc.
|
NEUTRAL | $2.93B | - | -5.8% | -6.8% | $22.97 | Compare |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
NEUTRAL | $2.96B | - | -3.7% | -5.4% | $51.39 | Compare |
|
PRVA
Privia Health Group, Inc.
|
NEUTRAL | $3.02B | 126.42 | 4.0% | 1.1% | $24.02 | Compare |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
BEARISH | $2.82B | - | -9.3% | -4.3% | $22.75 | Compare |
CON
Concentra Group...
NEUTRAL
Mkt Cap
$2.9B
P/E
17.6
ROE
48.1%
Price
$22.82
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-17 | NEWTON WILLIAM KEITH | Chief Executive Officer | Gift | 89,081 | - |
| 2025-11-25 | ORTENZIO ROBERT A | Director | Gift | 100,000 | - |
| 2025-11-04 | ORTENZIO ROBERT A | Director | Stock Award | 7,748 | - |
| 2025-11-04 | THOMAS DANIEL J | Director | Stock Award | 7,748 | - |
| 2025-11-04 | BONNER BRIGID A | Director | Stock Award | 15,496 | - |
| 2025-11-04 | PEGUS CHERYL | Director | Stock Award | 7,748 | - |
| 2025-11-04 | NELSON SU ZAN CPA | Officer | Stock Award | 60,000 | - |
| 2025-11-04 | GALLARA GIOVANNI | Officer | Stock Award | 60,000 | - |
| 2025-11-04 | ANDERSON JOHN R. | Officer | Stock Award | 60,000 | - |
| 2025-11-04 | KENDALL DANIELLE | Officer | Stock Award | 40,000 | - |
| 2025-11-04 | DEVASIA THOMAS A | Officer | Stock Award | 60,000 | - |
| 2025-11-04 | CONSER JONATHAN P. | Officer | Stock Award | 60,000 | - |
| 2025-11-04 | MCANDREW DOUGLAS R. | Officer | Stock Award | 60,000 | - |
| 2025-11-04 | KOSUTH MICHAEL A. | Officer | Stock Award | 60,000 | - |
| 2025-11-04 | NEWTON WILLIAM KEITH | Chief Executive Officer | Stock Award | 225,000 | - |
NEWTON WILLIAM KEITH
Chief Executive Officer
2025-12-17
89,081 shares
ORTENZIO ROBERT A
Director
2025-11-25
100,000 shares
ORTENZIO ROBERT A
Director
2025-11-04
7,748 shares
THOMAS DANIEL J
Director
2025-11-04
7,748 shares
BONNER BRIGID A
Director
2025-11-04
15,496 shares
PEGUS CHERYL
Director
2025-11-04
7,748 shares
NELSON SU ZAN CPA
Officer
2025-11-04
60,000 shares
GALLARA GIOVANNI
Officer
2025-11-04
60,000 shares
ANDERSON JOHN R.
Officer
2025-11-04
60,000 shares
KENDALL DANIELLE
Officer
2025-11-04
40,000 shares
DEVASIA THOMAS A
Officer
2025-11-04
60,000 shares
CONSER JONATHAN P.
Officer
2025-11-04
60,000 shares
MCANDREW DOUGLAS R.
Officer
2025-11-04
60,000 shares
KOSUTH MICHAEL A.
Officer
2025-11-04
60,000 shares
NEWTON WILLIAM KEITH
Chief Executive Officer
2025-11-04
225,000 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
DEF 14A
8-K
10-K
8-K
8-K
10-Q
8-K
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
7 analysts
Wells Fargo
2026-03-05
Overweight
Overweight
RBC Capital
2026-02-02
Outperform
Outperform
Past News Coverage
Recent headlines mentioning CON from our newsroom.
Newest → oldest
No matching news yet.